NanoLogix Inc (NNLX)

[kphone2004]

To explain why recipients are receiving in this email what they may view as redundant:

NanoLogix sends out updates to those who subscribe to our Newsletter Service. Those updates are sent to a few hundred subscribers and a few members of the media who happen to have subscribed, while press releases over the "wires" are viewed by many thousands. While the updates meet the requirements for dissemination of some company information, they are not press releases. Historically, NanoLogix has issued a number of updates and has then consolidated those, after editing, into what results as a press release. It has come to Management's attention that this fact is little understood. The updates reach such a small audience that, after much discussion, we have decided that we will only use this venue in the future to send a courtesy edition of issued press releases on the day of release. The reasons for this vary, but primarily it is being done to reduce the number of attacks upon NanoLogix by stock manipulators and others who may utilize update information in their strategies to damage honest investors' interests. These attacks upon the company and it's officers have increased dramatically as our good news has increased with sales, alliances, and technology developments. While we are essentially Teflon-coated when it comes to insults and abuse, our shareholder base may not be. Enough said on that topic. Enjoy the news below. The paper is written by a leading Biomedical Research Center, the name of which we are NOT permitted to use in anything we write on our website, for marketing material at the ASM or other meetings, or in an update. Those are the rules by which we abide.

The press release below is being released at 06:00 hours on 1/5/2016

NanoLogix Announces Publication of a Study in Journal of Microbiology and Experimentation
January 5, 2016 06:00 AM Eastern Standard Time
HUBBARD, Ohio (MarketWired)--NanoLogix, Inc. (NNLX), an innovator in the rapid detection, identification and determination of the antibiotic resistance and sensitivity of bacteria, is very pleased to announce publication in the Journal of Microbiology and Experimentation of a peer-reviewed study demonstrating dramatically extended shelf life and high-temperature durability of filled petri plates packed in NanoLogix-manufactured gas-charged FlatPacks. The study was performed by one of the world’s largest and most prestigious Biomedical Research Centers.
The results of the study demonstrated room temperature shelf life of typical petri plates filled with Tryptic Soy Agar (TSA) of at least 24 months and high-temperature durability to 30 days at 60° Centigrade (140° Fahrenheit) for Tryptic Soy, Chocolate, and Blood Agars. The study compared the NanoLogix FlatPacked plates with competitor’s plates. The competitor’s plates became desiccated and unusable after four months during the long-term shelf life study and desiccated and unusable after two days into the 30-day high temperature phase of the study.
NanoLogix has been running their own room temperature shelf life tests on sample TSA plates over a timeline that predates and extends beyond the results of the peer-reviewed study referred to in this release and has recently surpassed the four-and-a-half-year mark for viable room temperature storage of TSA plates.
The implications for the published results are vast, with many and varied potential uses of extended life ambient temperature storable petri plates in both domestic and international settings.
The FlatPack packaging that enabled these results is currently patented in the United States, the PRC, New Zealand, and South Africa, with EU and other patents pending.
Access the study here: http://medcraveonline.com/JMEN/JMEN-03-00075.pdf
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused on rapid diagnostics and petri plates. Its products offer accelerated detection and identification of microorganisms. In addition to medical, National Defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology, microbial physiology, pharmacology, and antibiotic sensitivity.
For more information visit: http://www.nanologix.com
This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Contacts
NanoLogix, Inc.
Carol Surrena, 330-534-0800
[e-mail]